Technologies

Exiris makes use of several platform technologies for target identification and validation. In addition, Exiris is developing its own antibody and drug conjugate technologies: Cancer stem cell platform, Drug conjugate technology and Antibody ID technology.

read more

Services

Exiris provides contract research services and collaborative development agreements using its innovative technology platforms: CSC Platform, Target ID, Drug-Conjugate platform, Custom human mAb production, Biomarker discovery and (…)

read more

Job opportunities

Ph.D. OPEN POSITION

MARIE S. CURIE INNOVATIVE TRAINING NETWORKS RESEARCH AND TRAINING PROJECT

Sponsored by the European Community under the Marie Skłodowska-Curie Actions (MSCA) Programme.

APPLICATION DEADLINE:
November 20, 2019

read more
07Oct

Exiris presents a “High Complexity-High Efficiency Human Antibody Phage Display Library” at the Festival of Biologics (FOB) 2019, Basel 15-17 October 2019

Exiris Human Antibody Phage Display Library for identification of high affinity monoclonal antibodies, without need of further affinity maturation, will be presented at the FOB.. Read More →

Contact us

Exiris srl

Laboratories:
Via Castel Romano 100
00128 Roma RM – Italy

Legal address:
Via Savona 6
00182 Rome – Italy

+39 06 50576530
www.exiris.it
info@exiris.it